Cost pressures and recognition of the limitations of liver biopsy have led to an increasing desire for non-invasive tests to assess both the stage of liver fibrosis and, more importantly, the rate of progression of fibrogenic chronic liver diseases (CLD). In the last decade, many studies have been dedicated to the search of non invasive markers able to provide accurate information about liver fibrogenesis activity and fibrosis stage in patients with chronic, potentially progressive hepatic diseases.
Prijshistorie
* Prijshistorie bevat geen data van Amazon, Amazon Marketplace.
Prijzen voor het laatst bijgewerkt op: